Compositions and methods of double-targeting virus...

Details Compositions and methods of double-targeting virus... Compositions and methods of double-targeting virus...

2006-04-11

2006-04-11

Wilson, James O. (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S026200, C536S026210, C536S026220, C536S026230, C536S026700, C536S026800, C536S116000, C536S120000

Reexamination Certificate

active

07026469

ABSTRACT:
The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds, which comprise a phosphocholine moiety covalently conjugated with one or more therapeutic agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds, which comprise an alkyl lipid or phospholipid moiety covalently conjugated with a therapeutic agent (e.g., a nucleoside analogue). The invention also includes pharmaceutical compositions for combating cancer and facilitating delivery of a therapeutic agent to a mammalian cell. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to combat a cancer or to facilitate delivery of a therapeutic agent to a mammalian cell.

REFERENCES:
patent: 2086585 (1937-07-01), Taub et al.
patent: 2087132 (1937-07-01), Taub et al.
patent: 2108765 (1938-02-01), Domagk
patent: 2209383 (1940-07-01), Bock
patent: 2439969 (1948-04-01), Fourneau
patent: 2445393 (1948-07-01), Fourneau
patent: 2513747 (1950-07-01), Sallman et al.
patent: 2606909 (1952-08-01), Blicke
patent: 2689790 (1954-09-01), Mowry et al.
patent: 2950253 (1960-08-01), Kling et al.
patent: 3054678 (1962-09-01), Michener et al.
patent: 3694473 (1972-09-01), Eibl et al.
patent: 4093714 (1978-06-01), Tolman et al.
patent: 4096278 (1978-06-01), Queuille
patent: 4119714 (1978-10-01), Kny et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4221732 (1980-09-01), Oette et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4291024 (1981-09-01), Turcotte
patent: 4329302 (1982-05-01), Hanahan et al.
patent: 4426525 (1984-01-01), Hozumi et al.
patent: 4444766 (1984-04-01), Bosies et al.
patent: 4471113 (1984-09-01), MacCoss
patent: 4540521 (1985-09-01), Garst et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4619917 (1986-10-01), Lee et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4661509 (1987-04-01), Gordon et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4797497 (1989-01-01), Schammel
patent: 4816450 (1989-03-01), Bell et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4826823 (1989-05-01), Cook et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837023 (1989-06-01), Eibl
patent: 4841039 (1989-06-01), Chu et al.
patent: 4880782 (1989-11-01), Eckstein et al.
patent: 4921951 (1990-05-01), Shuto et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 4997761 (1991-03-01), Jett-Tilton
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5138045 (1992-08-01), Cook et al.
patent: 5221696 (1993-06-01), Ke et al.
patent: 5496546 (1996-03-01), Wang et al.
patent: 5512671 (1996-04-01), Piantadosi et al.
patent: 5614548 (1997-03-01), Piantadosi et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5770584 (1998-06-01), Kucera et al.
patent: 5830905 (1998-11-01), Diana et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5891874 (1999-04-01), Colacino et al.
patent: 5922757 (1999-07-01), Chojkier
patent: 5962437 (1999-10-01), Kucera et al.
patent: 6030960 (2000-02-01), Morris-Natschke et al.
patent: 37 26 945 (1989-02-01), None
patent: 40 10 228 (1991-10-01), None
patent: 199 14 474 (1999-10-01), None
patent: 0 094 586 (1983-11-01), None
patent: 0 109 255 (1984-05-01), None
patent: 0 142 333 (1985-05-01), None
patent: 0 145 303 (1985-06-01), None
patent: 0 146 258 (1985-06-01), None
patent: 0 310 109 (1989-04-01), None
patent: 0 335 396 (1989-04-01), None
patent: 0 348 859 (1990-01-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 416 401 (1991-03-01), None
patent: 0 434 450 (1991-06-01), None
patent: 0 632 048 (1995-01-01), None
patent: 2 239 243 (1991-06-01), None
patent: 42-13841 (1967-08-01), None
patent: 61-238793 (1986-10-01), None
patent: 1029312 (1989-01-01), None
patent: 08-268890 (1996-10-01), None
patent: 10-101591 (1998-04-01), None
patent: 90/00555 (1990-01-01), None
patent: 90/05736 (1990-05-01), None
patent: 90/15601 (1990-12-01), None
patent: 91/05558 (1991-05-01), None
patent: 91/09602 (1991-07-01), None
patent: 91/18914 (1991-12-01), None
patent: 91/19726 (1991-12-01), None
patent: 92/03462 (1992-03-01), None
patent: 92/06192 (1992-04-01), None
patent: 93/00910 (1993-01-01), None
patent: 93/08807 (1993-05-01), None
patent: 93/16091 (1993-08-01), None
patent: 93/16092 (1993-08-01), None
patent: 93/17020 (1993-09-01), None
patent: 93/21191 (1993-10-01), None
patent: WO 94/28908 (1994-12-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
Surles , American Oil Chemists Society, vol. 28(1), pp. 55-57, 1993. (of record—cited in 1449).
Meyer, J. Med. Chem. vol. 34, pp. 1377-1383, 1991. (of record—cited in 1449).
Hong et al., J. Med. Chem., vol. 33, pp. 1380-1385, 1990 (of record—cited in 1449.
Bartlettt, 1996, Infectious Diseases in Clinical Practice 5:172-179.
Braekman et al., 1997, Proc. Amer. Soc. for Clinical Oncology, Abstract #810.
Capizzi, 1996, Investigational New Drugs 14:249-256.
De Clercq, 1995, Journal of Medicinal Chemistry 38:2491-2517.
Del Pan et al., 1997, Proc. Amer. Soc for Clinical Oncology, Abstract #1384.
Eron et al., 1998, AIDS 12:F181-F189.
Fauci, 1996, Nature {New Biology} 384:529-534.
Gill et al., 1987, Annals of Internal Medicine 107:502-505.
Hong et al., 1990, Journal of Medicinal Chemistry 33:1380-1386.
Hong et al., 1990, Cancer Res. 50:4401-4406.
Hostetler et al., 1990, Journal of Biological Chemistry 265:6112-6117.
Hostetler et al., 1991, Journal of Biological Chemistry 266:11714-11717.
Krugner-Higby et al., 1995, AIDS Res. & Human Retrovir. 11:705-712.
Kucera et al., 1990, AIDS Research & Human Retroviruses 6:491-501.
Kucera et al., 1992, In: Novel Membrane Interactive Ether Lipids With Anti-Human Innumodeficiency Virus Activity, Aloia et al., eds., Membrane Interactions of HIV, pp. 329-350.
Kucera et al., 1998, Antiviral Chemistry and Chemotherapy, 9:157-165.
Larder et al., 1989, Science 243:1731-1734.
Marx et al., 1988, Journal of Medicinal Chemistry 31:858-863.
Meyer et al., 1991, Journal of Medicinal Chemistry 34:1377-1383.
Morris-Natschke et al., 1986, Journal of Medicinal Chemistry 29:2114-2117.
Morris-Natschke et al., 1993, Journal of Medicinal Chemistry 36:2018-2025.
Piantadosi et al., 1991, J. Med. Chem. 34:1408-1414.
Poiesz et al., 1980, Proc. Natl. Acad. Sci. U.S.A. 77:7415-7419.
Richman et al., 1987, New England Journal of Medicine 317:192-197.
Steim et al., 1990, Biochemical & Biophysical Research Communications 171:451-457.
Sarbone et al., 1988, Annals of Internal Medicine 108:534-540.
Surles et al., 1993, Lipids 28:55-57.
Hendrickson, H., et al., A Facile Asymmetric Synthesis of Glycerol Phospholipid via Tritylglycidol Prepared by the Asymmetric Epoxidation of Allyl Alcohol. Chem. Phys. Lipids, 1990, vol. 53, No. 1, pp. 115-120, Abstract.
Gordeev, K., et al., Synthesis of Thio Analogs of Platelet Activating Factor (PAF), Bioorg. Khim., 1986, vol. 12, No. 7, pp. 951-955, Abstract.
Hong, C., et al., Nucleoside Conjugates. 15. Synthesis and Biological Activity of Anti-HIV Nucleoside Conjugates of Ether and Th

Affiliated with

Also associated with

Rating

Compositions and methods of double-targeting virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods of double-targeting virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of double-targeting virus... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3579773